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Abstract
Cell-associated receptor for urokinase plasminogen activator (uPAR) is released as both full-length soluble uPAR (suPAR) and
cleaved (c-suPAR) form that maintain ability to bind to integrins and other receptors, thus triggering and modulating cell
signaling responses. Concerning HIV-1 infection, plasma levels of suPAR have been correlated with the severity of disease,
levels of immune activation and ineffective immune recovery also in individuals receiving combination anti-retroviral
therapy (cART). However, it is unknown whether and which suPAR forms might contribute to HIV-1 induced pathogenesis
and to the related state of immune activation. In this regard, lymphoid organs represent an import site of chronic immune
activation and virus persistence even in individuals receiving cART. Lymphoid organs of HIV-1+ individuals showed an
enhanced number of follicular dendritic cells, macrophages and endothelial cells expressing the cell-associated uPAR in
comparison to those of uninfected individuals. In order to investigate the potential role of suPAR forms in HIV-1 infection of
secondary lymphoid organs, tonsil histocultures were established from HIV-1 seronegative individuals and infected ex vivo
with CCR5- and CXCR4-dependent HIV-1 strains. The levels of suPAR and c-suPAR were significantly increased in HIV-
infected tonsil histocultures supernatants in comparison to autologous uninfected histocultures. Supernatants from
infected and uninfected cultures before and after immunodepletion of suPAR forms were incubated with the chronically
infected promonocytic U1 cell line characterized by a state of proviral latency in unstimulated conditions. In the contest of
HIV-conditioned supernatants we established that c-suPAR, but not suPAR, inhibited chemotaxis and induced virus
expression in U1 cells. In conclusion, lymphoid organs are an important site of production and release of both suPAR and c-
suPAR, this latter form being endowed with the capacity of inhibiting chemotaxis and inducing HIV-1 expression.
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Introduction
Immunological hallmarks of HIV-1 infection are the progressive
depletion of CD4+ T lymphocytes cells, immune dysfunction and
chronic cell activation and inflammation [1,2], even in virologi-
cally suppressed patients receiving combination antiretroviral
therapy (cART). Chronic inflammation is a major driver of co-
morbidities and, indeed, HIV-1 infected persons under therapy
still have a shorter life expectancy and are at higher risk to develop
non-infectious diseases than age-matched uninfected persons [3,4].
Inflammation and immune activation also control virus replica-
tion, thereby participating to cell-cell spreading of HIV infection
and homeostatic proliferation of the viral reservoir [5].
Crucial events of HIV-1 induced pathogenesis occur in
secondary lymphoid organs such as tonsils and lymph nodes
(LN), in which both chronic immune activation and viral
spreading occur during the clinically silent phase of infection
[6,7,8,9,10,11]. Moreover, anti-retroviral drugs not always reach
effective concentrations in lymphoid organs, which represent
important viral reservoirs also in individuals under cART allowing
virus propagation at levels believed to be insufficient to select for
drug-resistance but sufficient for replenishing the viral reservoir
[12,13,14,15].
HIV-1 infection is known to perturb the plasminogen
activator (PA) system. In this regard, binding of the urokinase
PA (uPA) to uPAR induces activation of uPA, followed by
transformation of plasminogen into plasmin [16], a protease
that degrades fibrin in D-dimer [17]. Both uPA and plasmin
cleave uPAR in the linker region connecting domain I and II,
resulting in the presence of cell-associated cleaved uPAR (c-
uPAR, composed by domains II and III). Therefore, uPAR
might be present at the cell membrane as both full-length and
cleaved form (uPAR and c-uPAR, respectively), and the two
receptors are also shed as soluble molecules (suPAR and c-
suPAR, respectively) by the action of phosphatidylinositol-
specific phospholipase D acting at the GPI-anchor shared by
both uPAR and c-uPAR [18,19]. Plasma levels of suPAR, c-
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suPAR and D-dimer have been correlated with the severity of
HIV-1 disease and state of immune activation even in
individuals under cART [20,21,22,23,24,25,26,27]. Of note is
the fact that the plasma levels of suPAR and D-dimer in HIV-
1+ individuals have been shown to represent predictors of
disease progression, opportunistic diseases and mortality inde-
pendently of viremia levels and of CD4+ T cells counts and that
they were correlated with other inflammatory markers
[20,21,22,23,24,25,26,27]. These observations support the
hypothesis that these mediators might play an active role in
inflammatory processes and inflammation-driven HIV-related
comorbidities. In vitro, we and others have previously demon-
strated that uPA inhibits virus expression in chronically infected
cells and HIV-1 replication in acutely infected primary cells and
cell lines [28,29] in a signaling-dependent manner [28,30,31]
and that suPAR prevented this effect [32]. However, whether
HIV-1 infection affects the uPA/uPAR system in lymphoid
organs and whether such a system plays a role in HIV-1
infection in these organs is currently unknown.
To address these questions, tonsils and LN from uninfected and
HIV-1+ individuals, and tonsils from one HIV-1+ patient receiving
cART, were investigated for expression of uPA/uPAR compo-
nents. In addition, some of these tissues were infected ex vivo. The
kinetics of expression of soluble and tissue-associate uPA, uPAR, c-
uPAR, PA inhibitor-1 (PAI-1), CCL2/monocyte chemotactic
protein-1 (MCP-1) and HIV-1 replication were evaluated.
In the present study we have also investigated the expression of
the chemokine CCL2/MCP-1, because it has been shown to be
upregulated by HIV-1 infection both in vitro and in vivo [33,34,35]
with an overlapping pattern to that of the uPA/uPAR system
[35,36,37]. In fact, both CCL2/MCP-1 [38] and suPAR [20]
levels have been correlated with HIV-1 disease progression.
Furthermore, uPA has been reported to increase CCL2/MCP-1
expression [39] whereas CCL2/MCP-1 was shown to reduce uPA
secretion [40]. Finally, c-suPAR was demonstrated to inhibit
CCL2/MCP-1 induced chemotaxis [41].
Furthermore, we here report that c-suPAR, but not suPAR,
present in the conditioned culture supernatants from ex-vivo and
in vivo HIV infected histocultures modulated the chemotaxis and
virus expression in the chronically infected cell line, U1.
Our study provides the first evidence for a distinct role of cell-
associated and soluble forms of uPAR in terms of expression in
lymphoid organs infected with HIV-1. We also provide evidence
for an active role of one of its soluble forms, i.e. c-suPAR, in terms
of inhibition of chemotaxis and induction of virus expression. This
study bears a relevant translational component in terms of its
potential exploitation for the design of novel therapeutic strategies
aimed at controlling immune cell activation and HIV-1 reactiva-
tion in HIV-infected individuals under cART.
Materials and Methods
Analysis of Human Secondary Lymphoid Tissues from
HIV-1+ and Control Seronegative Individuals
Tonsils and LN from uninfected and therapy-naı¨ve HIV-1+
individuals were collected and drawn at the ‘‘Luigi Sacco’’
Hospital, Milan, during a period of 8 years (1994–2001). Nine
tonsils (4 from uninfected and 5 from HIV-1+ individuals) and
20 LN (12 from uninfected and 8 from HIV-1+ individuals)
were examined for this study (Table 1). Tonsils from HIV
uninfected individuals were used to match the clinical condition
present in HIV-1+ individuals. All tonsils were from individuals
affected by bacterial tonsillitis and were surgically removed after
antibiotic therapy. LN were obtained from patients undergoing
surgical resection of large bowel because of non-neoplastic
disease. Tissues were fixed in 10% buffered formalin and
embedded in paraffin. Informed consent was signed and
obtained from all participants.
Ex vivo Histocultures and HIV-1 Infection of Human
Tonsils
Tonsils from 46 HIV-uninfected subjects were collected at the
Ospedale San Raffaele, Milan, after receiving formal written
waiver from the institutional review board (Ethic Committee,
Ospedale San Raffaele) and signed written informed consent from
the patients. Tonsillectomy was performed because of frequent
annual relapsing tonsillitis; tonsils were surgical removed after
antibiotic therapy.
Tonsils were cultivated and infected ex vivo according to
published protocols [42,43]. Briefly, 9 tissue blocks were placed
on medium-hydrated collagen sponge (Gelfoam; Johnson&John-
son, Skipton, UK) and infected with 5 ml of viral stocks from the
reference CCR5-dependent (R5) and CXCR4-dependent (X4)
Table 1. Clinical parameters of seronegative and HIV-1+individuals used for retrospective analysis.
HIV-1 Uninfected HIV-1+
Tonsils
Number 4 5
Median age (range) 20 years old (16–24) 21 years old (16–26)
Sex 3 M, 1 F 4 M, 1 F
Histological diagnosis Follicular hyperplasia (4/4) Follicular hyperplasia (5/5)
Lymph nodes
Number 12 8
Median age (range) 59 years old (30–75) 42 years old (30–51)
Sex 7 M, 5 F 6 M, 2 F
Histological diagnosis Follicular hyperplasia (7/12), normal histology (5/12) Follicular hyperplasia (3/8), normal histology (5/8)
Tonsils with histological diagnosis of follicular hyperplasia from HIV infected and uninfected individuals were analyze.
Lymph nodes with follicular hyperplasia and normal histology from HIV infected and uninfected individuals were use. n; number of individuals, y; years, M; male, F;
Female.
Age is report as median and range of distribution in brackets.
doi:10.1371/journal.pone.0070606.t001
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HIV-1 strains BaL and LAI/IIIB, respectively, that were loaded
on top of each tissue block. Twenty-seven tissue blocks (subdivided
onto 3 collagen sponges) were used for each experimental
condition, and used for in vitro histoculture, formalin-fixed/
paraffin-embedded for histology and immunohistochemistry,
snap-frozen in liquid nitrogen for Western blot analysis.
The hyperplastic tonsils from a single HIV-1+ individual under
cART (male, 26 years old, and cART composed of tenofovir/
emtricitabina/efavirenz, with undetectable plasma viremia, ,37
copies/ml, at the time of tonsillectomy) were also collected. This
case was code as MA35.
Immunohistochemistry (IHC)
IHC analysis was performed on formalin-fixed/paraffin-em-
bedded tissues, as previously reported [44,45]. Briefly, sections
were mounted on super-frost slides (Bio-Optica, Milan, Italy), de-
waxed in xylene, rehydrated in ethanol and pretreated in a
microwave oven (59-two cycles. 780 W, 0.01 M citrate buffer).
Then, the slides were incubated for 2 h at room temperature with
a rabbit anti-human uPAR antibody (Ab; 6.3 mg/ml, 1:500
dilution), rabbit anti-human uPA Ab (5.7 mg/ml, 1:1,000
dilution), mouse anti-human HIV p24 Ab (clone Kal-1, Dako,
Denmark, 1:50 dilution) [45]. The reactions were revealed by
Universal HRP-Polymer Biotin-free detection system (MACH4,
BioCare Medical, USA) with 3,3-diaminobenzidine free base
(DAB) as chromogen. Negative controls were by omission of the
primary Ab. Blinded semi-quantitative count of immunostaining
was performed by using a 4-point scale. The most highly reactive
area was chosen for each sample and immunostaining was
quantified by counting positive cells in five 206fields according
to the following rules: 0 (no staining),+(,25% of immunoreactive
cells),++(25–75% positive cells),+++(.75% of immunoreactive
cells).
Double immunohistochemical reactions were performed with
the following Abs: mouse anti-human CD68 monoclonal Ab
(mAb; clone KP1; BioCare; 1:500 dilution), directed against a
fixative-resistant epitope on the macrophage-restricted form of the
CD68 molecule; mouse anti-human CD20 mAb (clone L26; Dako,
1:200 dilution) to detect B lymphocytes; mouse anti-human CD3
mAb (clone PS1; BioCare, 1:100 dilution) to detect T lympho-
cytes; mouse anti-human CD35 mAb (clone Ber-MAC-DRC,
Dako, 1:200 dilution) to detect follicular dendritic cells (FDC).
Specific secondary Abs conjugated with peroxidase and alkaline
phosphatases were chosen (MACH2 Double Stain 2; BioCare): the
first reaction was developed by using DAB as chromogen (brown
staining) and the second reaction by using Vulcan Fast Red (red
staining).
Quantification of HIV-1 Replication in Histoculture
Supernatants
Culture supernatants bathing 3 collagen sponges were harvested
every 3 days, pooled and clarified by centrifugation and 0.22 mm
filter filtration and stored at 280uC. The supernatant was then
tested for the presence of HIV-1 by means of Mg++-dependent
reverse transcriptase (RT) activity, as reported [42].
Quantification of uPA, suPAR, PAI-1, CCL2/MCP-1, and
Lactate Dehydrogenase (LDH) in Histocultures
Supernatants
The levels of uPA, suPAR, PAI-1 and CCL2/MCP-1 were
detected by ELISA (R&D Systems, MN, USA), and of LDH [46]
by using commercial kit (Sigma, MO, USA).
Western Blot Detection of suPAR forms and of HIV-1 p24
Gag
Both full-length and cleaved uPAR and suPAR forms and of
HIV-1 p24 Gag present either at the cell level or in the culture
supernatants were identified by Western blotting [47]. Briefly, 27
tissue blocks were lysed in 1 ml of lysis buffer (50 mM Tris HCl
pH 7.5, 150 mM NaCl, 0.5% NP-40, 0.5% sodium dehoxycholate
and 2 ml of protease inhibitor cocktail by Sigma): tissues were
vortex and kept at 4uC on a rotating wheel for 4 h, spun down at
4uC and clarified supernatant collected. Supernatants containing
HIV-1 were inactivated with 0.1% NP-40 for 4 h at 4uC on a
rotating wheel. Stably transfected HEK-293 cells were used as
positive controls for cell-associated and soluble forms of suPAR
[47].
For immunoblotting, tonsils lysates (20 mg), HEK-293-uPAR
and HEK-293-c-uPAR cell lysates (3 mg) or 20 ml of either
cultured tonsils or of HEK-293 transfected cell supernatants were
deglycosylated by treating with 4 ml of denaturing solution (0.5%
SDS, 10 mM DTT) and boiling for 3 min at 95uC to denaturate
uPAR and c-uPAR under mildly reducing conditions. To remove
N-linked glycosylation, 8 ml of deglycosylation buffer (PBS
containing 2.25% Triton X-100 and 65 mM EDTA) and 0.5 unit
of peptide-N-glycosidase F (from Elizabethkingia miricola, Sigma)
were added to each sample and incubated at 37uC overnight.
Immediately prior to SDS-PAGE, samples were add of 4X Laemly
buffer (containing 2% ß-mercaptoethanol) and boiled for three
min at 95uC.
Samples were loaded in 12% SDS-PAGE under reducing
conditions and transferred onto a nitrocellulose membrane.
Membranes were blocked for 2 h with 5% nonfat dry milk in
TTBS (20 mM Tris–HCl, pH 7.6, 150 mM NaCl, and 0.1%
Tween 20) and probed with either M2 anti-uPAR purified
polyclonal Ab (1 mg/ml) [47], anti-actin monoclonal Ab, mAb
(Sigma) or anti-HIV-1 p24 mAb (Acris Antibodies), followed by
appropriated secondary Ab/HRP conjugate (Amersham-GE), and
detection by ECL.
Transfer of Histocultures Conditioned Supernatant and
use of Lamivudine (3TC)
Conditioned culture supernatant (CCS) form either uninfected
or ex-vivo infected (R5 or X4 HIV-1 strain) tonsils was used in the
absence or presence of Lamivudine (3TC, Sigma, used at 10 mM).
Freshly established tonsil tissue blocks (n = 30) were suspended in
1 ml of clarified conditioned supernatant, with or without 3TC,
and 4 h later transferred on top of collagen sponges and cultivated
in standard conditions; tissue blocks treated with CCS added of
3TC were cultivated with culture medium containing Lamivudine
for the initial 3 days of histoculture.
Effect of Histocultures Conditioned Supernatants on
Chemotaxis and virus Reactivation in Chronically Infected
U1 Cells
The chronically infected promonocytic cell line U1 contains 2
copies of integrated HIV-1 provirus per cell and it is characterized
by a state of constitutive viral latency that can be reversed by
several stimuli [48,49,50,51]. U1 cells were cultivated in RPMI
containing 10% heat-inactivated FBS, 1% glutamine/penicillin/
streptomycin [52]. The tonsil culture medium (TCM) and the
CCS from either uninfected (Nil-c) or HIV-1 infected (R5-c, X4-c)
tissue blocks were immunodepleted with either control Ab or
polyclonal anti-human uPAR Ab (clone M2, recognizing both
suPAR and c-suPAR) [47] before stimulation of U1 cells.
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U1 cells (36105/ml) were cultivated for 4 days with the above
conditioned supernatants before quantification of the RT activity
content in CCS and of cell-associated HIV proteins by Western
blotting [52]. For chemotaxis, U1 cells (105) were suspended in
RPMI and placed in the upper part of Boyden chamber
(NeuroProbe, MD, USA) and separated from the bottom part
by PVP-free 5mm pore polycarbonate membrane, filled with 28 ml
of conditioned histocultures supernatants or TCM diluted 1:50 in
RPMI. After 5 h of incubation at 37uC, 5% CO2, cells from the
bottom chamber were cytospun on superfrost glass-slide, stained
with May-Grunwald Giemsa (MERCK) and mounted with Eukitt
mounting medium (Kindler GmbH, Freiburg, Germany). Pictures
were acquired at 106magnification with an optical phase contrast
microscope, and analyzed by FireCam software (Leica, Deerfield,
IL).
Statistical Analysis
Results are presented both as raw data and as means 6
standard error of the mean (SEM), differences considered
significant when p,0.05. Statistical analyses were performed
using the Graph Pad Prism 5 package. Differences in value
distribution between experimental conditions (HIV infected vs.
Nil) were assessed by the two-tailed paired T test. Two-tailed
Wilcoxon signed-rank test was used for comparing fold of
induction of paired experimental conditions (median of HIV-1
infected samples vs. median of 1 set for uninfected samples). Two-
tailed Mann-Whitney test was used for comparing distributions of
unmatched groups, and used for evaluating significances of data
from immunohistochemistry. Two-tailed Spearman test was used
to test the medians for correlation among variables that were not-
normally distributed.
Results
PA System Expression in Secondary Lymphoid Organs of
Uninfected and HIV-1+ Individuals
We here evaluated by immunohistochemistry (IHC) the
distribution and cellular expression of uPA and uPAR in lymphoid
organ sections of both HIV-1+ and control seronegative individ-
uals. The histological evaluation of hematoxylin-eosin slides
revealed follicular hyperplasia in 19/29 cases (all 9 tonsils and
10 lymph nodes) and the remaining 10 lymph nodes had normal
histology (Table 1). Hyperplastic tonsils and lymph nodes were
characterized by tissue enlargement due to the presence of
enlarged hyperplastic follicles within germinal centers.
The IHC analysis revealed HIV-1 p24Gag
+ cells in 4/8
hyperplastic lymphoid organs and in 1/5 lymphoid organs with
normal histology of infected individuals. As expected [53], HIV-1
p24Gag positivity was associated to FDC, as confirmed by double
staining with anti-CD35 mAb (data not shown).
UPAR+ cells were found in the germinal centers (GC) and inter-
follicular areas of lymphoid organs of both uninfected and HIV-1+
subjects (Figure 1A–1F). UPAR was expressed by macrophages
and FDC, as confirmed by double immunostaining with anti-
CD68 and anti-CD35 mAbs, respectively (Figure 1G, 1H);
endothelial cells were also positive for uPAR expression
(Figure 1I), whereas T and B lymphocyte were negative for this
antigen (data not shown). A semi-quantitative analysis of all
samples from lymphoid organs of HIV-1+ individuals revealed
higher levels of expression of uPAR than what observed in slides of
uninfected subjects (Figure 1L). Of interest, 5 out of 16 lymphoid
organs from uninfected individuals were negative for uPAR
expression, whereas all (13/13) lymphoid organs of HIV-1+
individuals were positive (Figure 1L).
Lymphoid organs of both uninfected individuals, either showing
normal histology or follicular hyperplasia, and those of HIV-1+
individuals displaying normal histology showed a low IHC score
for uPAR expression (Figure 1M). A higher IHC score for uPAR
expression was observed in hyperplastic lymphoid organs of HIV-
1+ individuals (Figure 1M). The increased number of uPAR+ cells
observed in hyperplastic lymphoid organs of HIV-1+ individuals
was not related to virus expression in that 50% of tissues were
negative for p24 Gag. Thus, increased number of uPAR+ cells in
lymphoid organs of HIV-1+ individuals was more likely conse-
quent to virus-induced immune activation, rather than local HIV-
1 expression.
Conversely, uPA was expressed by B lymphocytes, FDC and
some macrophages localized in the GC and inter-follicular areas in
lymphoid organs of both uninfected and HIV-1+ subjects
(Figure 2A–2B vs. 2D–2E). Lower expression of uPA+ cells was
found in LN with normal histology of uninfected and HIV-1+
subjects (Figure 2C vs. 2F), mostly expressed by FDC and some B
lymphocytes. The phenotype of uPA+ cells was confirmed by
double immunostaining (Figure 2G–2I), whereas T lymphocytes
(Figure 2L) and endothelial cells (data not shown) were negative
for this marker.
A semi-quantitative analysis of all lymphoid organs from HIV-
1+ patients revealed levels of uPA+ cells comparable to those of
uninfected subjects (Figure 2M). Considering separately lymphoid
organs with normal histology from those with features of
hyperplasia (Figure 2N), the IHC score revealed lower expression
of uPA in lymphoid organs with normal histology vs. hyperplastic
lymphoid organs, irrespectively of the HIV-1 infectious status.
Thus, increased number of uPA+ cells was typical of lymphoid
hyperplasia and was not strictly dependent upon infection.
Perturbation of CCL2/MCP-1 and of the PA System in
Tonsil Histocultures Infected ex vivo with HIV-1
In order to investigate whether HIV-1 infection could modulate
the PA system in secondary lymphoid organs, tonsil histocultures
from HIV-1 seronegative donors were infected ex vivo with either
R5 or X4 HIV-1 strains. Their culture supernatants were collected
and tested for virus replication by means of RT activity, presence
of dead cells, and levels of CCL2/MCP-1, uPA, suPAR, and PAI-
1. Tissue blocks were analyzed for histology, IHC and Western
blotting for expression of uPAR and viral proteins. Results are
presented as ratio of the levels of the analytes in infected vs.
uninfected tissues (Nil) to minimize inter-donor variability (Figure
S1).
Both R5 and X4 HIV-1 replication became evident 6 days after
infection (p,0.0001 for R5 and X4 strain at day 6, 9 and 12 vs.
Nil defined as 1, n = 31) and achieved a plateau between day 9 and
12 post-infection (Figure 3A); no differences were observed in the
replicative capacity of R5 and X4 HIV-1 strains (Figure 3A), as
also confirmed by IHC (Figure 3A and Figure S2A). HIV-1
infection did not influence cell mortality in the histocultures, as
indicated by the comparable levels of LDH detected in culture
supernatants of infected and uninfected tissues (Figure 3B). The
histological analysis of both infected and uninfected cultures
revealed that the typical structure of tonsils remained evident
(presence of GC and of inter-follicular regions), although a
decreased cellularity and sharpness of GC was observed at day 9
(Figure 3B) and 12 (not shown) of culture in comparison with
earlier time points. Thus, HIV-1 infection per se did not influence
tissue morphology and viability of tonsil histocultures.
We next searched for the release of CCL2/MCP-1 and
elements of the PA system by tonsil histocultures that either were
left uninfected or were infected with HIV-1.
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Figure 1. UPAR expression in tonsils and lymph nodes of uninfected and HIV-1+ individuals. Figures are representative of tonsils and
lymph nodes from uninfected and HIV-1+ individuals with hyperplastic and normal histology. Sections used for IHC were obtained from formalin-fixed
paraffin-embedded tissues, and the clinical parameters of donors are described in Table 1. Tonsils from either uninfected (panels A-C) or HIV-1+
individuals (panels D-F) show uPAR+ cells present both in the GC (arrows, GC) and in the inter-follicular area (IA). UPAR was expressed by
macrophages (panel G, double immunohistochemistry with CD68 shown in brown and uPAR in red), FDC (panel H, double immunohistochemistry
with CD35 shown in brown and uPAR in red) and endothelial cells (panel I, uPAR shown in brown) in both groups of patients. Panels A-F: Optical
Magnification (OM) 10x, panels G and H: OM 100x, panel I: OM 40x. Brown staining in panels G-H is indicated by an arrow. Immunohistochemical
score for the number of uPAR+ cells was evaluate for lymphoid organs of uninfected and HIV-1+ individuals; all lymphoid organs (panel L), normal vs.
hyperplastic lymphoid organs (panel M). Vertical and horizontal bars represent mean and SEM. Differences for the number of uPAR+ cells in the
different tissues and populations were tested by the two-tailed Mann-Whitney test (p values are indicated by asterisk * = 0.01–0.05; **0.001–0.01).
doi:10.1371/journal.pone.0070606.g001
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Figure 2. UPA expression in tonsils and lymph nodes of uninfected and HIV-1+ individuals. Tonsils from either uninfected (panels A-C) or
HIV-1+ individuals (panels D-F) showed uPA+ cells (in brown) predominantly in the GC. The phenotype of uPA+ cells was demonstrated by double
immunostaining (panels G-L): uPA (red) was expressed by B lymphocytes (CD20+, brown), FDC (CD35+, brown) and a few macrophages (CD68+,
brown), but not T cells (** CD3+, brown). Panels G-L: OM 10x. Panels M-O show OM at 100x. Brown staining in panels G-H is indicated by an arrow.
Immunohistochemical score for the number of uPA+ cells was evaluate for lymphoid organs of uninfected and HIV-1+ individuals; all lymphoid organs
(panel M), normal vs. hyperplastic lymphoid organs (panel N). Vertical and horizontal bars represent mean and SEM. Differences for the number of
uPA+ cells in the different tissues and populations were tested by the two-tailed Mann-Whitney test (p values are indicated by asterisk * = 0.01–0.05;
**0.001–0.01).
doi:10.1371/journal.pone.0070606.g002
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Figure 3. Ex-vivo HIV-1 infection of tonsil histocultures increases the soluble levels of CCL2MCP-1, suPAR, c-suPAR and the number
of uPAR+ cells. Tonsil blocks were left either uninfected (Nil) or were infected with R5 or X4 HIV-1 strain. Every 3 days the culture conditioned
supernatants were tested for the levels of viral replication (RT activity), lactate dehydrogenase (LDH), CCL2/MCP-1, suPAR, uPA and PAI-1. The results
are reported as fold vs. Nil (absolute values are shown in the Figure S1). Panels A (n = 31), B (n = 31) and C (n = 28) show fold of HIV-1 replication, LDH
and CCL2/MCP-1 levels vs. Nil, respectively, as measured in the culture supernatants The panels below show the IHC detection of HIV p24Gag
measured 6 days post-infection and hematoxylin-eosin staining at day 9 after infection. Panel D (n = 28) shows fold of suPAR levels vs. Nil measured in
the culture supernatants. Panel E (n = 7) shows the IHC score in terms of number of uPAR+ cells in Nil and ex-vivo infected tonsil histocultures at the
indicated time points after infection (Day 0 is the time of surgical removal); the right panels show the IHC of uPAR+ cells (brown) 9 days post-
infection. Panel F shows western blot analysis evaluating for the presence of both uPAR and c-uPAR and of HIV-1 p24 Gag release in the culture
supernatants of tonsils left uninfected (Nil) or infected in vitro for the indicated time points after infection. Panels G (n = 21) and panel H (n = 21) show
the fold of uPA and PAI-1 levels vs. Nil measured in the culture supernatants. The vertical and horizontal bars represent the mean and SEM. Black dots
and triangles in panels A-E and G-H represent data from tonsils infected ex-vivo with R5 and X4 strain, respectively; white circles in panel E represent
data from uninfected ex-vivo tonsils. Statistical significance is indicated by asterisks (*** =,0.001); 2-tailed paired t test (panel A), 2-tailed Wilcoxon
signed-rank test (panels C and D). Pictures are at 406magnification.
doi:10.1371/journal.pone.0070606.g003
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CCL2/MCP-1 was detectable in uninfected histoculture
supernatants at different times of culture (Figure S1C). As
expected, HIV-1 replication increased the secreted levels of
CCL2/MCP-1 at day 9 and 12 (Figure 3C). The levels of suPAR
were similar in the supernatants of uninfected and infected tissues
during the first 6 days of infection, but raised in infected cultures 9
and 12 days post-infection (Figure 3D), in coincidence with virus
replication and increased CCL2/MCP-1 secretion.
Immediately after tonsillectomy, no/very few cells were uPAR+,
but their number expanded during the first 6 days and remained
constant in the second week of culture (Figure 3E). Both R5 and
X4 HIV-1 infection enhanced the number of uPAR+ cells after
6 days of infection and for the following week of culture
(Figure 3E). Of note is the fact that the increased levels of suPAR
from HIV infected tissue blocks at day 9 and 12 of culture followed
the kinetics of virus replication and the increased number of
uPAR+ cells observed after 6 days of culture.
Next, we evaluated which suPAR forms were released by both
infected and uninfected histocultures. Supernatants collected from
uninfected cultures contained both suPAR and c-suPAR. Both R5
and X4 HIV-1 infection increased their release as detected 9 and
12 days post-infection (Figure 3F), when virus replication was also
detected by either RT activity (Figure 3A) or p24Gag accumulation
in culture supernatants (Figure 3F). There was no preferential
release of suPAR vs. c-suPAR as also observed in the plasma of
HIV-1+ individuals [22,23].
In contrast to these findings, and despite the bi-directional
relationship between uPA and CCL2/MCP-1 [39,40], HIV-1
infection of tonsil did not modulate the levels of soluble uPA and
the number of uPA+ cells in the same tonsil histocultures
(Figure 3G and Figure S2B). However, human tonsils represent
a more complex environment than cell lines [39,40] used to
describe the bi-directional relationship between uPA and CCL2/
MCP-1, suggesting compensatory mechanisms in lymphoid organs
regulating uPA and CCL2/MCP-1 expression upon HIV
infection. Moreover, ex vivo HIV-1 infection of tonsil histocultures
did not modulate the release of soluble levels of PAI-1 (Figure 3H).
Correlation between suPAR and CCL2/MCP-1 Secretion in
Tonsil Histocultures
Unlike what observed in uninfected histocultures (Figure 4A), a
significant correlation was observed between the secreted levels of
suPAR and those of CCL2/MCP-1 in supernatants of both R5
and X4 HIV-1 infected tissue blocks (Figure 4B and 4C),
indicating that during HIV-1 infection a common mechanism of
regulation or interdependency of the expression of suPAR and
CCL2/MCP-1 occurred.
To investigate the potential capacity of HIV-1 replication, or its
consequences on the microenvironment, on suPAR and MCP-1
secretion we next investigated whether supernatants from infected
histocultures could induce expression of suPAR and CCL2/MCP-
1 in the absence or presence of HIV reverse transcriptase inhibitor
Lamivudine (3TC). Freshly established tonsil histocultures were
incubated with R5 or X4 conditioned supernatants (R5-c and X4-
c, respectively). Both supernatants productively infected the new
tissue blocks inducing similar levels of virus replication, which was
blocked by 3TC (Figure 4D) in the absence of significant changes
in terms of cytopathicity in the different experimental conditions
(Figure 4E). The levels of both suPAR (Figure 4F) and CCL2/
MCP-1 (Figure 4G) released by the new histocultures were not
modified by 3 days incubation with 3TC in uninfected conditions.
In contrast, both R5-c and X4-c induced higher levels of suPAR
and CCL2/MCP-1 vs. uninfected cultures and this effect was not
affected by 3TC (i.e. it occurred independently of virus replication,
Figure 4F and 4G). In order to unveil the ‘‘carry-over’’ effect of the
conditioned supernatants, both suPAR and CCL2/MCP-1 levels
were measured after 4 h of culture showing no differences between
uninfected tissue blocks and those that had been previously
incubated with R5-c and X4-c (Figure 4F and G). These findings
were confirmed by IHC, revealing that 3TC-treated tissues were
negative for p24 Gag expression (Figure 4H and I) and that the
number of uPAR+ cells were similar in both 3TC-treated and
untreated tissues (Figure 4L and M). According to these findings,
the levels of suPAR and of HIV-1 in the culture supernatants were
not inter-correlated (n = 28, data not shown), as previously
reported in vivo [20].
C-suPAR, but not suPAR, Modulated U1 Cell Chemotaxis
and virus Expression Induced by the Conditioned Culture
Supernatant (CCS)
As uPAR, suPAR binds uPA and integrins [54]. On the other
side c-suPAR binds to formyl peptide receptor (FPR) FPRL1,
inducing chemotaxis of FPR+ cells [41,55]. C-suPAR was also
shown to induce the heterologous desensitization of chemokine
receptors, therefore inhibiting monocyte migration in response to
different chemokines, including CCL2/MCP-1 [41,55]. Because
of the different composition of the extracellular milieu from Nil
and HIV-infected tonsils (as here shown for suPAR, c-suPAR and
CCL2/MCP-1 in the conditioned mediums collected after 9 and
12 days post-infection), we evaluated the contribution of suPAR
and c-suPAR to the modulation of biological activities of CCS
collected from uninfected and HIV-infected tonsil histocultures.
CCS were used as whole or immune-depleted of suPAR forms, by
using a polyclonal anti-uPAR Ab (M2 clone) recognizing a domain
shared by both suPAR and c-suPAR [47], and eventually
reconstituting them with exogenous suPAR or c-suPAR. Im-
munodepletion completely removed suPAR forms, as evaluated by
ELISA, but did not influence CCL2/MCP-1 levels or HIV
content, as measured by ELISA or RT activity levels (data not
shown), respectively. We next tested these different CCS
preparations for their capacity to modulate either chemotaxis or
HIV-1 expression in U1 cells, known to constitutively express both
FPRL1 and several integrins. In addition, we have previously
reported that U1 cells are characterized by secreting ca. 10-fold
less suPAR than primary monocytes [32].
U1 cells migrated in response to fMLP, CCL2/MCP-1,
CXCL12/Stromal Cell-Derived Factor-1a (SDF-1a) and c-
suPAR, but not to suPAR (Figure 5A). CCS of uninfected tonsil
histocultures (Nil-c) failed to induce chemotaxis of U1 cells and
removal of both suPAR forms did not affect this lack of response
(Figure 5B, left panel). When CCS derived from either R5 or X4
infected tonsils (R5-c or X4-c) were tested for induction of U1 cell
chemotaxis, no activity was detected; however, immunodepletion
of both suPAR and c-suPAR from CCS of infected histocultures
resulted in a significant migration of U1 cells. Of importance,
addition of c-suPAR, but not of suPAR, to the immuno-depleted
CCS inhibited the chemotactic response (Figure 5B, middle and
right panels).
None of the above mentioned chemotactic stimuli tested
induced HIV-1 expression in U1 cells (Figure 5C), whereas virus
expression was detectable following PMA stimulation (Figure 5C).
In contrast, CCS from uninfected tonsil (Nil-c) induced virus
expression and removal of both suPAR and c-suPAR further
increased it (Figure 5D). Of note is the fact that the reconstitution
of the immunodepleted CCS with c-suPAR, but not with suPAR,
decreased the levels of virus expression to that of non-immunode-
pleted supernatant (Figure 5D). In contrast, although also CCS
from either R5 or X4 infected tonsils (R5-c or X4-c, respectively)
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Figure 4. HIV-1 conditioned microenvironment increases the levels of suPAR and CCL2/MCP-1 in uninfected tonsil histocultures.
Panels A, B and C show the correlation between the levels of CCL2/MCP-1 and suPAR in the conditioned supernatants of Nil (A) and ex vivo infected
tonsils (B, R5 strain; C, X4 strain); correlations were analyze by the Spearman test and correlation coefficients (r) and statistical significance (p) are
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shown within each panel. Dotted curves represent the 95% confidence band of best-fit regression lines. The conditioned supernatants from R5 (R5-c)
and X4 (X4-c) infected tissue blocks were used for infecting novel tissue blocks, in the absence or presence of 3TC (10 mM; added during tissue blocks
preparation to the conditioned culture supernatant during the 4 h period of incubation, and for the initial 3 days of cultivation of tissue blocks on
collagen sponges). Aliquots of culture supernatant were also collected after 4 h of histoculture for measuring the contribution of the ‘‘carry over’’.
Culture supernatants were test for RT activity (D), number of cell death (E), levels of suPAR (F) and CCL2/MCP-1 (G). Two-tailed paired T test (n = 7) was
used for statistical analysis, and p values are indicated by asterisks (** = 0.001–0.01; *** =,0.001). Panels H and I show the IHC analysis of HIV-1 p24Gag
expression in tonsil histocultures infected with R5-c in the absence and presence of 3TC, respectively. Lack of p24 positivity was observed in 3TC-
treated tissue. OM 20x. Panels L and M show the IHC analysis for the expression of uPAR in tonsils infected with R5-c in the absence and presence of
3TC, respectively. No difference of immunostaining was found. OM 20x. Vertical and horizontal bars represent the mean and SEM.
doi:10.1371/journal.pone.0070606.g004
Figure 5. Soluble and cleaved form of uPAR differently modulates chemotactic activity and HIV expression by conditioned
microenvironments. Chemotaxis of chronically infected monocytic cells was tested (n = 3) in response to: A. tonsil culture medium (TCM) and TCM
added of recombinant stimuli or purified c-suPAR and suPAR [76,77]; B. conditioned supernatant from uninfected tonsils (Nil-c), R5 infected tonsils
(R5-c) and X4 infected tonsils (X4-c) immunodepleted with either control immunoglobulins (IP w Ig) or polyclonal anti-human uPAR Ab (IP w M2) [47]
or M2-depleted supernatants reconstituted with 100 ng/ml of purified c-suPAR or suPAR. Migrated cells toward TCM was 2569 (n = 3). HIV-1
expression from U1 cells was tested (n = 3) by cultivating them with the same stimuli and conditions used and described for chemotaxis assay (panels
C-D). Gray squares in panel D represent the value of input virus in the conditioned supernatants at the end of the 4 days of culture. CM from ex vivo
uninfected and infected tonsils were collected after 9 days of histoculture. Vertical and horizontal bars represent mean and SEM. Two-tailed paired T
test was used for statistical analysis, and p values are indicated by asterisks (* = 0.01–0.05; ** = 0.001–0.01; *** =,0.001).
doi:10.1371/journal.pone.0070606.g005
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induced virus expression from U1 cells, removal of both suPAR
forms reduced the levels of virus expression (Figure 5D). Addition
of c-suPAR, but not of suPAR, restored the levels of virus
expression to that observed in non-immunodepleted supernatant
(Figure 5D). Therefore, the contribution of c-suPAR to chemotaxis
and HIV expression was opposite in the context of CCS obtained
from infected and uninfected tonsils in that c-suPAR did not
modulate chemotaxis but inhibited HIV expression induced by
CCS from uninfected tonsils, whereas it inhibited the chemotactic
potential and contributed to HIV-1 expression induced by CCS
from infected tonsils. Although in the present study we have not
further investigated the underlying mechanisms responsible for this
functional dichotomy, it is conceivable that c-suPAR might
interfere with the intracellular signaling pathways induced by
different factors present in the CCS of infected and uninfected
histocultures, known to secrete different levels of cytokines and
chemokines [56,57] able to influence both chemotaxis and HIV-1
expression.
Expression of the PA System Elements in Tonsil
Histocultures of a Single HIV-1+ Individual (MA35)
Receiving cART
The hyperplastic tonsils of a single HIV-1+ individual receiving
cART were collected, processed and cultured as above reported
for tissues of uninfected individuals. Although cART induced
undetectable levels of plasma viremia (,37 copies/ml for this
individual at the time of tonsillectomy), the tonsils from this
individual were positive for HIV p24Gag expression (Figure 6A). In
addition, MA35’s tonsils expressed uPAR and c-uPAR at higher
levels than what observed in tonsils from uninfected individuals
(Figure 6B). Higher level of suPAR were measured after 3 days of
his tonsil histocultures vs. those established from 31 uninfected
individuals (18,601 vs. 7,12562461 pg/ml, respectively; n = 31,
day 3 for Nil, Figure S1). Both full-length and c-suPAR forms were
detected (Figure S3).
As observed with tonsil histocultures infected ex vivo, the CCS
from MA35 revealed that c-suPAR, but not suPAR, inhibited U1
cell chemotaxis (Figure 6C). CCS from MA35 histoculture
sustained HIV-1 expression from U1 cells, as evaluated both in
the culture supernatant (Figure 6D) and at cellular level (Figure 6E)
and the removal of both suPAR and c-suPAR from CCS by use of
the M2 Ab resulted in decreased expression of HIV-1 proteins in
U1 cells. Addition of c-suPAR (but not suPAR) to the
immunodepleted MA35’s CCS restored normal levels of RT
activity released in the culture supernatant (Figure 6D) and
expression of viral proteins (Figure 6E). Thus, we can hypothesize
that the pathway(s) inducing virus expression in the presence of c-
suPAR is likely acting at the transcriptional level, at least in U1
cells. Further studies will assess the mechanism sustained by c-
suPAR inducing HIV transcription, either by c-suPAR inducing
intracellular signaling or by its ability to modulate signalings by
different ligands.
Discussion
In the present study, we have observed that HIV-1 infection of
secondary lymphoid organ histocultures induced an increase in the
number of macrophages, FDC and endothelial cells expressing
uPAR. However, such an increase was observed only in
hyperplastic lymphoid organs, and not those with normal
histology, of HIV-1+ individuals suggesting an indirect role for
infection in terms of promoting a state of immune activation. In
addition, we have observed that HIV-1 infection of lymphoid
histocultures enhanced the expression of cell-associated uPAR and
c-uPAR and their release in culture supernatants, independently of
the levels of virus replication as it was also observed when the
infection was carried on in the presence of Lamivudine. These
observations were confirmed in tonsil histocultures established
from a single HIV-1 infected individual receiving cART. Finally,
we collected evidence that c-suPAR, but not full length suPAR,
present in CCS interferes with both chemotaxis and HIV-1
expression in U1 cells although with an opposite pattern as a
function of whether the CCS were derived from infected or
uninfected histocultures.
Our findings extend the characterization of the PA system to the
pathophysiology of secondary lymphoid organs, relevant sites of
viral persistency even under cART, and identify lymphoid organs
as one of the main site of production and release of soluble forms
of uPAR. In particular, we suggest that upregulation of suPAR
expression is not directly linked to the levels of virus replication in
lymphoid organs, but it is more likely mediated by modification of
the extracellular microenvironment consequent to virus infection.
In this regard, our findings support previous reports showing that a
state of chronic inflammation caused increased levels of cell-
associated uPAR on several cell types, including HIV-target cells
and endothelial cells [58,59,60] and that the levels of suPAR in
HIV-1+ individuals under cART were correlated to those of
soluble TNF receptors [61].
The increased levels of suPAR detected in ex vivo infected tonsil
histocultures were ca. 50% higher than those of parallel uninfected
tissues. Of note is the fact that the same range of suPAR increase
has been correlated with progression and poor prognosis in
different diseases [62,63], including HIV-1 infection [20] and
cancer [64], sharing some levels of systemic inflammation and
chronic immune activation as common denominator. Moreover,
lymphoid organs released both suPAR and c-suPAR, indicating
that they are a source of plasma-associated suPAR and c-suPAR,
likely contributing to the immune dysfunction and systemic
diseases typically observed in HIV-infected individuals. For
example, binding of suPAR to ß3 integrin expressed by podocytes
was correlated to the pathogenesis of focal segmental glomerulo-
sclerosis [65], a disease also associated to HIV-1 infection [66].
We and others have previously investigated the uPA and HIV-1
infection in primary cells or cell lines. In these systems we reported
that uPA inhibited the replication or expression of HIV-1 whereas
suPAR prevented its effects [32]. However, the potential role of
the cleaved form of the receptor was not investigated in these cells.
We here report that c-suPAR modulated monocyte chemotaxis
and HIV expression induced by the CCS of both uninfected and
HIV-1 infected tonsil histocultures. The increased level of c-
suPAR was responsible for blocking the migration of U1 cells and
boosting HIV-1 expression by U1 cells in response to factor(s)
present in CCS from ex-vivo infected histocultures and histocultures
established from a single infected individual receiving cART.
In spite of the high levels of inflammatory cytokines during
chronic HIV disease [67] there is no inflammatory infiltrate in
tissues and organs, differently from what is observed with bacterial
infections in which the PA system plays a defensive mechanism by
favoring recruitment of neutrophils and monocytes [68]. Because
in both bacterial and HIV infections the levels of both suPAR and
c-suPAR are increased, these findings suggest that c-suPAR might
participate to the different immune defense strategies. Indeed,
activities of c-suPAR are different in the context of uninfected
tonsils, unveiling its ability to influence biological processes in
response to pathological events as consequent to the modification
of the extracellular environment, as here tested in terms of CCS.
In this study we did not assess for the different mechanism
responsible for the dichotomous effect of c-suPAR in the context of
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Figure 6. Plasminogen activator system in tonsils of HAART-treated HIV-1+ individual. Tonsils from one HIV-1+individual under cART
(MA35) tested positive for HIV p24Gag in the germinative center of tonsil (panel A, OM 10x), and expressed both uPAR and c-uPAR (panel B; seven
tonsils from uninfected individuals (#36–46) were used as reference control). Sections used for Western blotting were from snap-frozen tissue blocks,
whereas lysates from stably transfected HEK cells expressing uPAR and c-uPAR were used as positive controls; because of high levels of expression of
these antigens in HEK cells actin was not detected at exposure time used for showing actin from tissue lysate. Chemotaxis of (panel C) and HIV
expression from (panel D) U1 cells were measured as described in Figure 3. Gray squares in panel D represent the value of input virus in the
conditioned supernatants at the end of the 4 days of culture. Cell-associated HIV proteins were measured in U1 cells cultivated for 4 days with the
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uninfected and HIV-1 infected lymphoid organs. However, the
increased levels of CCL2 and c-suPAR observed in HIV-1 infected
tonsils (irrespectively of the viral strain) might suggest that a
common mechanism through which the chemotactic signal
triggered by two ligands leads to cross-interference, as previously
reported for CCL2 and CCL5 [69], whereas removal of c-suPAR
unleashes the chemotactic potential of CCL2.
As to virus expression, both cytokines and chemokines over-
expressed by HIV infected tonsils [56,57], including CCL2 as
shown in this study, own the capacity of modulating HIV-1
replication [67]. In this regard, it is of particular note that the
intracellular signaling by FPRL1, the receptor engaged by c-
suPAR, has been previously reported to mediate heterologous
desensitization of CCR5 and CXCR4, thus inhibiting cellular
entry of CCR5- and CXCR4-using HIV strains [70]. Nonetheless,
FPRL1 can also be engaged by some HIV envelopes to gain entry
into target cells [71,72]. Among HIV target cells, FPRL1 is
expressed by monocytes and macrophages, and chemokines such
as CCL5/RANTES [73] and CCL3/MIP-1a [74] sustain virus
replication and inhibit HIV post-entry steps in macrophages,
respectively. Thus, engagement of FPRL1 by c-suPAR can
profoundly modulate HIV-1 replication. Further studies directed
toward the characterization of pathways modulated by c-suPAR
are necessary to clarify the role of the PA system in HIV-1
pathogenesis, in particular addressing for the role of infected
macrophages in lymphoid organs. In this regard, pprevious reports
have investigated the uPA and HIV infection in primary cells or
cell lines, thus lacking the proper environment, structure and
complexity typical of lymphoid organs. Nonetheless, the action
mechanism of the cleaved form of the receptor, such as
modulation of biological activities by tissue-derived extracellular
environment, could not have been properly revealed with models
using single cell population or in vitro cell stimulation/activation/
differentiation. Therefore, a novel aspect of this study is the
definition of the distinct roles of the two forms of suPAR in the
tonsil-derived extracellular environment.
Thus, we here provide evidence that the uPA system in
lymphoid organs is affected by HIV-1 infection, resulting in
increased expression and release of both the suPAR and c-suPAR
forms. In addition, we provide evidence that c-suPAR might play a
regulatory role in HIV-1 infection of secondary lymphoid organs,
by interfering with both chemotaxis and virus replication. Our
findings also provide a framework for further studies aiming to
assess if suPAR represents a feed-forward loop sustaining virus
expression while influencing the presence of HIV-target cells in
lymphoid organs of HIV-1+ individuals even in the presence of
cART (in which condition suPAR levels remain elevated).
In conclusion, our study identifies the cleaved form of suPAR as
a candidate therapeutic target to be considered in cART-treated
individuals for its potential to modulate the state of immune
activation and residual viremia, as well as in the context of
protocols aiming at reactivating latent provirus to achieve a
functional cure of HIV-1 infection [75].
Supporting Information
Figure S1 Absolute levels of HIV replication, number of
dead cells, uPA, PAI-I, suPAR and MCP-1 in culture
supernatants. Levels of reverse transcriptase activity (indicative
of productive virus replication), number of death cells (estimated
by the levels of LDH), and of CCL2/MCP-1, uPA, PAI-1 and
suPAR were measured in culture supernatants collected every 3
days post infection. Vertical and horizontal bars represent mean
and standard error of the mean. (A) Two-tailed paired T test was
used to analysis efficiency of infection at each time point of culture.
The absolute levels of replication over the uninfected tissue block
reached statistical significance at day 6, day 9 and day 12
(p,0.0001 for both R5 and X4 strain vs. Nil, n = 31), and not
statistical significance between R5 and X4 strains (p = 0.28 at day
6, p= 0.16 at day 9, p = 0.48 at day 12, n = 31) (Figure 1A). (B) To
estimate the number of dead cells soluble levels of lactate
dehydrogenase (LDH) [46] were measured in culture supernatants
collected every 3 days post infection, and converted into number
of dead cells by using standard curve prepared from known
numbers of PBMC that underwent 5 cycles of freez-thaw [32].
Absolute numbers of dead cells were not different between Nil vs.
R5 infected tissue blocks, Nil vs. X4 infected tissue blocks and R5
vs. X4 infected tissue blocks (Figure 2B), with data analyzed by
two-tailed paired T test (n = 30). (C) Levels of CCL2/MCP-1
were evident during the entire period of histoculture, and the two-
tailed paired T test revealed statistical difference between
uninfected and R5 or X4 infected tissue blocks at day 9 and 12
of culture (p,0.0001 for R5 vs. Nil, p = 0.0024 for X4 vs. Nil at
day 9; p,0.0001 for both R5 and X4 strain vs. Nil at day 12,
n = 28). No statistical significance between R5 and X4 strains was
monitored at each time point (p = 0.58 at day 9, p= 0.13 at day
12, n= 28). Indeed, statistical analysis (two-tailed paired t test)
revealed that fold of CCL2/MCP-1 levels from HIV infected
tissue blocks increased from day 6 to day 9 (R5 day 6 vs. day 9
p,0.0001; X4 day 6 vs. day 9 p= 0.0009, n = 26) reaching a
plateau at day 12 (R5 day 9 vs. day 12 p= 0.42; X4 day 9 vs. day
12 p= 0.95, n= 26), along the increased virus replication. (D)
Absolute levels of suPAR increased during the entire period of
histoculture, and statistical significance between uninfected and
HIV infected tissue blocks was reached at day 12 post infection
(two-tailed paired t test, Nil vs. R5 infected tissue blocks
p = 0.0023, Nil vs. X4 infected tissue blocks p = 0.0061, n= 28).
No statistical significance between R5 and X4 strains was
monitored at each time point, including day 12 post-infection
(p = 0.93, n= 28). SuPAR levels from HIV infected tissue blocks
increased from day 6 to day 9 (R5, day 6 vs. day 9 p,0.0001; X4,
day 6 vs. day 9 p,0.0001, n= 26) reaching a plateau at day 12
(R5, day 9 vs. day 12 p= 0.27; X4, day 9 vs. day 12 p=0.84,
n = 28). (E) Absolute levels of uPA increased over the entire period
of culture, in particular after six days of culture (two-tailed paired t
test; Nil at day 6 vs. Nil at day 9 p= 0.0022, n = 26), and both R5
and X4 infection did not modify its expression when compared to
uninfected tissue blocks. (F) Absolute levels of PAI-1 increased
after 3 days of culture and then remained constant up to day 12 of
culture, and both R5 and X4 infection did not modify its
expression.
(TIF)
Figure S2 In vitro HIV infection and modulation of the
number of HIV+ and uPA+ cells. IHC analysis for HIV
p24Gag and uPA antigens was used for estimating the number of
cells expressing virus and uPA at day 0, 6 and 12 post infection.
(A) HIV p24+ cells were detected starting from 6 days of
histoculture. No difference between viral strains was observed. (B)
UPA+ cells were present in tonsils at the time of surgical removal
stimuli reported at the bottom of the panel (E) and viral proteins were identified based on their molecular weight (right side of the panel). PMA
(10 nM) was used as positive control for inducing virus expression (n = 3).
doi:10.1371/journal.pone.0070606.g006
Cleaved suPAR in HIV Infected Lymphoid Organs
PLOS ONE | www.plosone.org 13 July 2013 | Volume 8 | Issue 7 | e70606
(Day 0), increased during the first six days of culture (day 0 vs. day
6 p,0.0001, n = 7) and remained constant in the following week.
Both R5 and X4 infection did not modify the number of uPA+
cells over than what observed in uninfected tissue blocks. Data
were analyzed by two-tailed paired T test, and p values indicated
by asterisks (** = 0.001–0.01; *** =,0.001).
(TIF)
Figure S3 Tonsils of HAART-treated HIV+ individual
released both full-length and cleaved suPAR. UPAR forms
and HIV p24Gag were evaluated in the conditioned supernatant
after 3 days of histoculture of tonsils from MA35. In parallel,
conditioned supernatants from in vitro HIV infected tonsils were
also measured.
(TIF)
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